A gene-directed enzyme pro-drug therapy (GDEPT) based on purine nucleoside phosphorylase (PNP) 
Introduction
Prostate cancer (PC) is a major cause of death and morbidity in men of the western world. 1, 2 Most PCs are adenocarcinomas that arise in epithelial cells from peripheral acinar glands and follow a predictable pattern. Early tumors grow slowly and are organ-confined, while poorly differentiated tumors have a worse prognosis associated with their tendency to metastasize. Organ-confined PCs can be treated by prostate surgery or by targeted irradiation using brachytherapy or external beam radiotherapy, but these treatments can have distressing side-effects and 30-50% will eventually recur. 3, 4 Endocrine therapy for cancer that has spread beyond the prostate leads to periods of remission, but quality of life can be adversely affected and objective tumor regression is seen in only 2-3% of patients. Androgen-independent (AI) tumors for which there is no effective cure emerge in approximately 20% of cases after only 12-18 months. 5 Developing gene therapy technologies should, for these reasons, be applied to PC, especially given that the pros- tate is a 'dispensable' organ, allowing scope for treatments that kill prostate epithelial cells, whether normal or malignant.
Strategies under consideration include both ex vivo and in vivo genetic modifications (for review, see . Ex vivo strategies are based on manipulation of tumor cells in vitro to stimulate a host immune response, such as the use of GM-CSF-transduced prostate cancer vaccines. 9 In vivo strategies for local delivery aim to overcome a genetic defect involved in PC progression (for example by inserting a tumor suppressor gene 10 or by inducing apoptosis, 11 or to express an enzyme which converts a prodrug into an anti-cancer metabolite in the target tumor cells (gene-directed enzyme prodrug therapy, GDEPT). 12, 13 Such therapies can be further refined by the use of prostate-specific promoters to drive gene expression. 7, [14] [15] [16] [17] [18] [19] For systemic therapy, replication competent adenoviruses that are controlled by a tissue-specific promoter are under development. 20 Alternatively, tumor targeting can be achieved by altering the normal tropism of adenovirus infection. [21] [22] [23] [24] Several GDEPT systems are under investigation for cancer therapy, including PC. The most studied uses Herpes simplex virus-thymidine kinase (HSVtk) gene transduction in combination with the pro-drug ganciclovir (GCV). HSVtk phosphorylates GCV, converting it to a nucleoside analogue that terminates DNA synthesis leading to the death of dividing cells. HSV-TK-GDEPT has undergone a phase I clinical trial in patients with PC 25 with promising results. We have been investigating a GDEPT system which is more suitable for use in slow growing tumors, such as PC, where the fraction of dividing cells is low. 26 This is based on an E. coli enzyme, purine nucleoside phosphorylase (PNP) that converts purine pro-drugs to toxic metabolites. The compounds can be incorporated into both RNA and DNA, killing non-dividing, as well as dividing cells. 27 Moreover, the purine metabolites can diffuse readily both between and within prostate epithelial cells creating an efficient bystander effect. [27] [28] [29] We have shown that PNP-GDEPT works well against human AI PC-3 prostate cancer cells grown in vitro 30 or subcutaneously (s.c.) in nude mice.
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A recombinant human adenovirus (Ad5) containing the PNP gene controlled by the prostate-specific PSA promoter, together with the prodrug, 6-methyl-9-(2-deoxy-␤-D-erythro-pentofuranosyl) purine (6MEPDR, which is converted by PNP to 6 methylpurine, 6MEP) caused a 75% reduction in PC3 tumor growth, with a complete cure in 25% of mice, and significantly prolonged mouse survival, compared with a control virus that did not contain the active gene cassette. 18 An alternative prodrug for this system is fludarabine phosphate, which has been approved for clinical use for the treatment of leukemia. Fludarabine has a Km for PNP which is approximately 1000-higher than that for 6MEPDR, but of the PNP metabolites, 2-fluoroadenine (2FA) is approximately 100-fold more potent as a growth inhibitor than 6MEP. 28 Moreover, 6MEPDR needs to be chemically synthesized for use, whereas fludarabine phosphate is available commercially. For this reason, our in vivo experiments were confined to the use of fludarabine phosphate.
We have chosen to use recombinant adenovirus vectors for gene delivery to cancer cells because they can infect both dividing and non-dividing cells to achieve efficient, transient expression. However, pre-existing immunity against human adenoviruses that are endemic in man may compromise their use, depending on the route of inoculation. [31] [32] [33] In addition, CAR, the primary Ad5 receptor 34, 35 which is required for effective virus uptake, 36 is absent from certain human cell types. We are therefore assessing ovine adenovirus (OAdV) as a vector. OAdV is not neutralized by human antisera that neutralize Ad5. 37 OAdV uses a receptor that is uncharacterized, but distinct from CAR 38 and OAdV may be more effective for gene delivery in some cases. OAdV can deliver genes to various cell types but its replication in non-ovine cells is abortive, thus minimizing risks associated with replication-competent Ads.
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RM1 is an androgen-independent prostate cancer cell line derived by transformation of cells from the genital ridge of embryonic C57BL/6 mice with ras and myc oncogenes. 40 When implanted in appropriate locations, these cells can form tumors either s.c. or in the prostate, although tumor growth is rapid and aggressive, unlike prostate cancer growth in man. However, it was the only immunocompetent animal model available that could provide animals in sufficient numbers when this work was commenced. Studies in the RM1 model have shown that HSV-TK-GDEPT delivered by Ad5, together with GCV can partially inhibit orthotopic tumor growth. 41, 42 We wished to determine whether OAdV, like Ad5, was an efficient vector for delivering genes to target cells in the RM1 mouse model and whether a single intratumoral injection of vector could lead to sustained PNP expression that would be compatible with prodrug treatment for prostate cancer. Here we have constructed Ad520 and OAdV220 vectors that carry the PNP gene linked to the highly active, constitutive Rous sarcoma virus promoter 43 and compared their ability to deliver genes to RM1 cells in vitro. Given that the OAdV220 vector was highly efficient in vitro, we continued studies in vivo with this vector. We then examined the effect of OAdV220-mediated gene therapy with the prodrug, fludarabine phosphate, against RM1 tumor cells in vitro and in vivo. As there are limited models available for testing gene therapy for advanced prostate cancer, the RM1 model represents a worst-case scenario. Therefore we also tested the efficacy of the OAdV-delivered PNP GDEPT in a more representative model of human prostate cancer, PC-3 cells grown in nude mice.
Results

Transduction of RM1 cells by OAdV in vitro
It was previously shown that RM1 cells can be infected by OAdV217A, a virus that carries the HCMV promoter/GFP expression cassette. It was clear from the amount of transgene expression at 4 days after infection that transduction had occurred in proportion to the amount of input virus. 44 Similarly, Ad520 or OAdV220 was used to transduce RM1 cells at MOIs of 10 2 -10 4 opu/cell and PNP activity was assayed at 24 and 72 h after infection (Figure 1 ). For both viruses enzyme activity was greatest at the highest MOI, although with 10 4 opu/cell of OAdV220, PNP activity was probably outside the linear range of the assay. PNP expression by OAdV220 at 24 h after infection was close to maximal and did not increase substantially after 72 h. At both time-points expression by OAdV220 significantly exceeded that by Ad520 at the same MOI. As both viruses carried the identical expression cassette, the difference in expression most likely reflected the relative abundance of the respective, distinct receptors on RM1 cells. However, relative receptor affinity and internalization efficiency could also be factors. Collectively, these data suggest that OAdV220 is preferred over Ad5 vectors for further studies in this model system.
In vivo expression of transgene by OAdV220
To demonstrate gene transfer by OAdV in vivo and to examine the kinetics of gene expression RM1 tumors were established s.c. in C57BL/6 mice by injection of 2.5 × 10 5 cells. On day 0, when tumors had reached 5 × 5 mm in diameter, they were injected intratumorally (6 × 10 9 opu/tumor) once with OAdV220. Groups of three mice were killed on days 1, 2, 3, 4 and 6 after virus injection and homogenates of their tumors were tested for expression of PNP by monitoring the conversion of fludarabine to 2FA. After assay for 16 h, the different tumor lysates converted between 5 and 35% of available substrate to 2FA ( Figure 2 ). The rate of substrate conversion has been determined in nanomoles substrate/milligram tumor protein/hour (nmoles/mg/h). In each assay, 500 nmoles fludarabine was reacted with 0.5 mg of homogenate in a 16-h assay. Therefore, to determine the rate of substrate conversion by the homogenates/mg, the fludarabine conversion is multiplied by 2 (rate of conversion per mg) and divided by 16 to determine conversion per hour. On average, each mg of RM1 tumor converted 20 + 9.375 nmoles fludarabine/h, when tumors were processed the day following treatment with 6 × 10 9 particles of OAdV220 (Table 1) . PNP expression decreased gradually thereafter showing virtually no activity against fludarabine by day 6 after treatment.
This conversion was acceptable, as while fludarabine is a poorer substrate for PNP compared with 6MEPDR, its product, 2FA is around 100× more potent than the product of 6MEPDR, 6MP. 28, 45 Nevertheless, the data con- Gene Therapy firm that OAdV220 can effectively deliver the PNP gene expression cassette into tumors in vivo and that PNP expression is sustained over at least a 6-day period.
GDEPT in vivo Subcutaneous growth of RM1 cells transduced in vitro:
In contrast to human prostate cancers that grow slowly, RM1 tumors are very aggressive. To assess the effectiveness of the GDEPT system independently of the efficiency of gene delivery, cells were transduced with virus at the earliest opportunity. As accurate injection of tumors was difficult before their becoming palpable in vivo, an approach was adopted in which RM1 tumor cells were transduced with virus (or mock-transduced with buffer) in vitro before (day -1) their s.c. inoculation into mice on day 0. Mice were then treated with fludarabine phosphate or saline control from days 1-5. Effects on tumor growth and overall mouse survival were assessed. opu/cell. Mann-Whitney U analyses were used to assess the relative efficiencies at individual time points throughout the study. At day 14, fludarabine phosphate treatment resulted in a 22% and 36% reduction in mean tumor volume in the Mock and OAdV220 (10 2 opu/cell; not significant) groups, respectively. Overall, ex vivo transduction of OAdV220 at 10 3 and 10 4 opu/cell + fludarabine phosphate resulted in a 70% and 90% decrease in tumor growth over ex vivo transduction of OAdV220 alone at 10 3 and 10 4 opu/cell, respectively. At day 14, fludarabine phosphate treatment resulted in reductions of 80% (P = 0.0004, * * * ) and 98% (P Ͻ 0.0001, * * * ) in mean tumor volume in the OAdV220 10 3 and 10 4 opu/cell groups, respectively. At day 24, fludarabine phosphate treatment resulted in reductions of 75% and 96% in mean tumor volume in the OAdV220 10 3 and 10 4 opu/cell groups, respectively. By day 24, all treated mice, and 90% of control mice were still alive. However, overall survival of mice that received 10 3 or 10 4 opu/cell + fludarabine phosphate was improved in that 43% and 100%, respectively, were still alive at day 39 when their control groups had died from tumor burden. More importantly, by day 45, survival of mice that received 10 3 or 10 4 opu/cell + fludarabine phosphate was markedly prolonged with approximately 30% or 88%, respectively, still alive, whereas all other groups of mice had died between day 33 and 45. Furthermore, 75% of mice that received 10 4 opu/cell + fludarabine phosphate survived until day 114, with only two mice showing any tumor present out of the remaining six. Thus, when virus access to these rapidly growing cells was not restricted, the GDEPT showed a clear fludarabine phosphate-mediated dose-response related to the virus input/cell.
Subcutaneous RM1 tumor growth:
We next examined whether PNP-GDEPT could suppress the growth of preformed s.c. tumors in the presence of a functioning immune system. RM1 tumors were generated in C57BL/6 mice on day -5. On day 0, mice were treated with one intra-tumoral injection of OAdV220 or saline + fludarabine phosphate. A line of best fit was generated for each graph of tumor volume versus time and the ability to suppress tumor growth was determined from the days taken to reach the midpoint of tumor growth. Figure 4a shows that OAdV220 plus fludarabine phosphate reduced overall tumor growth by 35%, when compared with controls. Fludarabine phosphate alone had no effect on tumor growth compared with the Mock control. OAdV220 alone did not affect tumor growth or survival (data not shown). Between days 9 and 12 a temporary cessation of tumor growth occurred in the treated group. At day 12, when group comparison was still possible (ie control mice were still alive), there was a 59% reduction in mean tumor volume in the OAdV220/fludarabine phosphate group compared with those receiving fludarabine phosphate alone (P = 0.001, * * ). With this highly aggressive tumor model, around 70% of the mice died by day 16, regardless of the treatment. In the remaining 30%, PNP-GDEPT marginally increased survival by 2 days (all dead by day 21), compared with controls (all dead by day 19). Given the small numbers of mice at this time, the results were not considered significant.
Orthotopic RM1 tumor growth:
To mimic the likely clinical situation more closely, a single injection of OAdV220 or saline + fludarabine phosphate was used to treat RM1 tumors established by orthotopic implantation in C57BL/6 mice. Results were presented as tumor volume at death for two separate experiments (Figure 5a and b) . Data were presented separately as variations in prostate tumor size existed between experiments. In two separate experiments, there was a trend suggesting that treatment with OAdV220/fludarabine phosphate caused around a 25% decrease in tumor volume over mock virus/fludarabine phosphate (Figure 5a ) or OAdV220 alone (Figure 5b ). Given the variation in tumor volumes at death in the mice, larger numbers of mice would need to be treated to attain statistical significance of this effect. This is very difficult to achieve in a timely manner because of the surgical procedure involved. Histological analysis of three tumors/treatment group indicated that some necrosis of tumor cells was present, and there was a mild immune cell infiltration both at the periphery and in the center of the tumor. This was more pronounced than that seen following treatment of s.c. tumors.
Subcutaneous PC3 tumor growth:
To examine whether OAdV-mediated PNP-GDEPT could also suppress human prostate cancer growth, androgen-independent PC3 human prostate tumors were generated in BALB/c nude mice. Once these reached 5 × 5 mm, mice were treated with a single intra-tumoral injection of OAdV220 or virus dilution buffer followed by fludarabine phosphate (75 mg/m 2 /day) or saline i.p. for 5 days. Treatment groups included: fludarabine phosphate alone, OAdV220 alone and OAdV220 plus fludarabine phosphate. Data were presented as individual tumor volumes within each treatment group measured on days 4, 25 and 53, following intra-tumoral injection ( Figure 6 ). For ease of interpretation, a mean tumor volume (± s.e.m.) was calculated for each group. There was no difference in tumor volumes between groups of mice treated with fludarabine phosphate alone (mean 142.1 ± 21mm
3 ), OAdV220
Figure 
Discussion
The work reported in this paper shows that recombinant OAdV is a suitable vector for delivery of PNP-GDEPT to mouse and human prostate cancer cells in vitro and in vivo. Although it can bypass pre-existing immunity to human adenoviruses, OAdV does induce an immune response when given intravenously. 37 Thus, the efficacy of a second administration of vector, if required, may be compromised depending on the route of injection. [31] [32] [33] A second issue concerning this new vector is safety, particularly when all viral genes are present in recombinant viruses. This is the subject of continuing studies, but so far it has been shown that OAdV does not replicate in a variety of cell human lines, 39 nor does it transform rodent cells that are transformed by human AdV5. 46 In addition, intravenous administration of approximately 10 11 virus particles into SCID or BALB/c mice did not cause overt toxicity. 37 Tumors based on the RM1 cell line grown in C57BL/6 mice grow far more aggressively than does prostate cancer in man. However, it was the best available immuno-Gene Therapy (Figure 3a) . Mouse survival was increased in a dose-dependent manner ( Figure  3b ). As there is no suitable antibody available for PNP it was not possible to determine the percentage of cells that were transduced in this experiment and therefore, to estimate the potency of the GDEPT system. Treatment started later by injection of OAdV220 (6 × 10 9 opu/tumor) into pre-established s.c. tumors caused a temporary (3 day) delay in tumor progression and reduced growth overall by 35% (Figure 4a ). This was not associated with increased survival (Figure 4b ). Injection of OAdV220 (10 10 opu/tumor) into pre-established intraprostatic RM1 tumors followed by systemic fludarabine phosphate treatment resulted on two occasions in a trend towards reduced prostate volume at day 18 compared with treatment with fludarabine phosphate alone ( Figure  5a ) or virus alone (Figure 5b ), but there was considerable variation in tumor volume in all mice examined. In subsequent experiments (data not shown), when mice were killed at day 11, a 47% reduction in prostate volume was achieved using PNP-GDEPT with fludarabine compared with buffer alone. However, due to the complexities of surgery in this system, the kinetics of tumor growth were not examined so it is unknown whether a temporary cessation in tumor growth was achieved.
Figure 6 Effects of GDEPT in vivo: s.c. PC-3 tumor growth in nude mice. Established s.c. PC-3 tumors were injected intra-tumorally with
It was previously reported that at higher MOIs, OAdV induced an apparent cytopathic effect in human MRC-5 lung fibroblasts in vitro, but no virus was produced. 39 At higher MOIs of OAdV220 we observed a similar effect at approximately 4 days after infection in vitro on RM1 cells, but not on PC3 cells (data not shown). Although the molecular basis of this effect is not understood we considered whether augmentation of tumor cell killing might occur if transduction levels were high enough. However, pretransduction of RM1 cells with OAdV220 (10 4 opu/cell) only did not appreciably slow the growth of tumors in vivo compared with controls treated with fludarabine phosphate alone (Figure 3a) .
Studies in the RM-1 model were also performed by Eastham et al, 13 who used replication-deficient Ad5 to introduce HSVtk under the control of an RSV promoter (Ad-TK; 5 × 10 8 p.f.u.) to palpable s.c. tumors. GCV treatment (100 mg/kg) was given twice daily for 6 days. This strategy resulted in an 84% suppression of tumor growth on day 13 and promoted survival to a greater extent than in mice treated with control virus. Injection of Ad5-TK (5 × 10 8 p.f.u.) into pre-established prostatic RM1 tumors 7 days after implantation followed by systemic GCV (10 mg/kg) given i.p. twice daily resulted in an 80% reduction in prostate tumor growth compared with control mice killed on day 14. 41 In these studies and those of Eastham et al, 13 the viral dose was defined as infectious or plaque forming units (p.f.u.), but the opu/p.f.u. ratio was not specified. Thus it is difficult to compare results from these studies with those presented here. However, if standard methods were used to determine infectivity in that study, we estimate that the dose of Ad5-TK was at least five to 20 times greater than the dose of OAdV220 that we used. Notwithstanding the higher level of PNP expression in RM1 cells in vitro with OAdV220 ( Figure  1) , the lower levels of virus input in our studies was probably a significant contributor to the observed difference in efficacy between the two GDEPT systems following treatment of pre-established RM1 tumors. We previously showed that GDEPT using PNP was more effective in vitro than GDEPT using HSVtk when the same virus backbone and the same promoter were used. 30 However, penetration of the prodrug into the tumor cells is another factor that could impact on the efficacy of each GDEPT system. Clearly, the penetration of fludarabine phosphate into tumors established from pre-transduced RM1 cells in vivo was efficient as shown by the extensive virus/drug-dependent cell killing that was obtained. Whether there is a reduced penetration of fludarabine phosphate into pre-formed tumors in this system or in human tumors is not clear. Although fludarabine alone has a limited effect on prostate tumors in vivo, this could be for a variety of reasons, including the level of cytidine kinase expression 47 and low rate of cell turnover. 26 The ability of PNP to convert fludarabine to its toxic metabolite in target tumors is expected to be an important factor that determines efficacy.
Fludarabine phosphate can cause myelosuppression when used at a high dose in man. The question of the dosage used with GDEPT therefore needs consideration. With GDEPT, the effective dose of fludarabine phosphate given to C57BL/6 mice bearing RM-1 tumors was 600 mg/m 2 /day (Figures 3-5) , considerably less than the 1350 mg/m 2 /day for 7 days used by Parker et al, 27 to treat PNP-transfected glioma cell bearing mice. The effective dose that we used for treating nude mice carrying human prostate cancers was 75 mg/m 2 /day ( Figure 6 ). At this stage, lower doses have not been tried. The dose usually used in man is 25 mg/m 2 /day when a series of treatments, each for 5 days, is extended for up to 30 courses with cumulative toxicity. In a phase I trial, lymphopenia occurred at all doses of fludarabine phosphate given, but was reversed within 3 weeks following treatment. 48 Hence the dose in nude mice which provided significant tumor growth inhibition when used with vector was 3× higher than that usually used in man, but was given on one occasion only (ie for a course of 5 days), whereas in treating leukemia, up to 30 courses of treatment are given. Moreover, PNP breaks down the fludarabine phosphate to 2-fluoroadenine. Future GDEPT studies will be performed with lower doses of pro-drug to understand how low a fludarabine phosphate dose can be used in the human tumor bearing nude mouse model to achieve efficacy.
Fludarabine tolerance appears to be approximately 45 times higher in the mouse than in man, possibly due to the contrast in distribution of deaminase and phosphorylation enzymes that breakdown or metabolise fludarabine in the body. In various mouse and human tissues, the rates of deamination versus phosphorylation strongly favor deamination, 49 with the ratio of deamination rate to phosphorylation rate in the human brain being 505:1 and 20:1 for the mouse brain. 49 Deoxycytidine kinase and like enzymes are widely distributed throughout mouse tissues, in contrast to human tissues where enzyme activity occurs preferentially in thymocytes, lymphocytes Gene Therapy and possibly other hemopoietic precursors. 50 Fludarabine accumulation in such cells may explain the myelosuppression and lymphopenia observed when high doses are administered in humans. Given the restricted distribution of these enzymes in man compared to mouse it is quite likely that a lower dose of fludarabine delivered in a single course to humans in conjunction with a viral vector will be sufficient to provide efficacy against prostate cancer under conditions that should not be associated with toxicity.
This study also showed that recombinant OAdV is a suitable vector for the delivery of PNP-GDEPT to a human androgen-independent prostate adenocarcinoma based on PC3 cells grown s.c. in nude mice. These tumors grow more slowly in nude mice than RM1 cells in C57BL/6 mice, more closely reflecting the clinical situation. Growth of PC3 tumors in mice treated by intratumoral injection of OAdV220 plus systemic fludarabine phosphate was reduced by 77% when compared at day 53 to mice treated with fludarabine phosphate alone ( Figure 6 ). Treatment of mice with OAdV220 alone had no effect on tumor growth when compared with treatment with fludarabine phosphate alone. Significantly, there were four tumors in the OAdV220 plus fludarabine phosphate treatment group, which regressed completely and the remainder of the tumors in this group were substantially smaller than those receiving control treatments.
In summary, we have observed significant pre-clinical effects with OAdV-delivered, PNP-mediated GDEPT in two mouse models. Despite its aggressive nature, the RM1 model will be useful for the study of new therapeutic options, as, unlike models based on nude mice, it can reflect changes to the immune system stimulated by the therapy. Clearly, improvements in the ability to disseminate OAdV220 within the target tumor and/or the induction of an immune response against lysed tumor cells would further improve therapeutic efficacy. Furthermore, a GDEPT employing a prostate-specific promoter active in both androgen-dependent and -refractory prostate cell lines would offer a potential safety benefit compared with the constitutive promoter used in these studies.
Materials and methods
Cell lines and cell culture RM1 androgen-independent prostate cancer cells 40 were kindly provided by Dr T Thompson (Baylor College, Houston, TX, USA) and PC3 human prostate cancer cells were from ATCC. RM1 cells were grown in DMEM medium (GIBCO-BRL/Life Technologies, Grand Island, NY, USA) and PC3 in RPMI, in both cases containing 2 mM L-glutamine (GIBCO), 0.2 M HEPES buffer solution (GIBCO), sodium biocarbonate (0.85 g/l; Sigma Chemical, St Louis, MO, USA), penicillin G (2 units/ml)/ streptomycin sulfate (100 U/ml) (GIBCO), and 10% fetal calf serum (FCS; Trace Bioscientific, Sydney, Australia). The cells were free of mycoplasma and used in the log phase of growth. Cells were routinely harvested with 0.025% trypsin (GIBCO).
Mice
Male C57BL/6 and BALB/c nu/nu (nude) mice were bred and maintained at the Biological Resources Centre (BRC), University of New South Wales, (UNSW, Sydney, Australia) with access to mouse chow and acidified water ad libitum. They were used at 6-8 weeks of age. All studies were in accordance with guidelines of the Animal Care and Ethics Committee (AEC) of UNSW, and Prince Henry and Prince of Wales Hospitals, Sydney, Australia.
Recombinant adenovirus production and characterization
The ovine adenovirus vector OAdV220 containing a 522-bp portion of the Rous sarcoma virus 3' LTR linked to the E. coli PNP gene and bovine growth hormone (BGH) polyadenylation signal (RSV/PNP/BGH expression cassette) was constructed as follows. The same gene cassette was inserted into the E1A/B region of human Ad5 to create Ad520. The PNP portion of the PSA/PNP cassette in plasmid pXCX3 30 was excised by digestion with SpeI/BamHI and cloned into XbaI/BamHI-cut Bluescribe SK+ (Stratagene, San Diego, CA, USA). The BGH polyadenylation signal was obtained as a XhoI fragment and cloned into the SalI site of the preceding plasmid 3' to the PNP sequences. Unwanted internal sequences at the junction were removed by partial digestion with SacI, blunt ending, SmaI digestion and re-ligation. The resulting plasmid was digested with SacI/NotI and ligated with a poylinker that removed the SacI and NotI sites and inserted, 5' to the PNP gene, in order, sites for KpnI, BglII, SalI, MfeI, SpeI, AflII and SacI. The RSV promoter region was obtained from another plasmid as a XhoI fragment and cloned into the SalI site of the preceding plasmid. The assembled cassette was excised as a KpnI/XhoI fragment, cloned into the KpnI/SalI sites of plasmid pXCX3 and Ad520 was rescued by recombination in 293 cells as previously described. 30 The assembled cassette was also excised as a BglII/XhoI fragment, blunt-ended and cloned into the blunt-ended XbaI site of plasmid pGem11zf+ (Promega, Madison, WI, USA), where the orientation with ApaI at the 5' end was selected. The cassette was subcloned as an ApaI/NotI fragment into the same sites of plasmid pOAdV200 between the pVIII and fiber genes of OAdV. 51 The new plasmid, pOAdV220 was digested with KpnI to release the linear infectious genome. Viral DNA was transfected into permissive CSL503 cells with Lipofectamine (GIBCO-BRL/Life Technologies) as previously described. 51 When a cytopathic effect became evident, virus was passaged on fresh CSL503 cells to obtain a stock and characterized by determining that its genome had the expected restriction enzyme profiles. Virus was propagated in CSL503 cells and recovered from the medium by centrifugation on to a cushion of CsCl (1.5 g/cc). Virus in residual unlysed cells was recovered by lysis in PBS containing NP40 (0.25% v/v), combined with virus from the medium, purified by CsCl step and density gradient centrifugation 52 and stored in virus storage buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 75 mM KCl, 10% glycerol). For both Ad520 and OAdV220, the number of particles recovered was determined by optical density (optical particle units; opu) 53 and infectivity (infectious units, IU) was determined by a limiting dilution assay on CSL503 or 293 cells, respectively. The opu/IU ratio for OAdV220 preparations used here was in the range of 100-350:1. For Ad520 virus the ratio was 100:1.
Prodrugs
For in vivo work, non-toxic doses of fludarabine phosphate (FLUDARA; Schering, Germany) were determined by preliminary experiments where a range of doses was administered intraperitoneally (i.p.) daily for 5 days to groups of five non-tumor-bearing C57BL/6 mice or BALB/c nu/nu (nude) mice (data not shown). For GDEPT in C57BL/6 mice, fludarabine phosphate was administered i.p. daily for 5 days at 600 mg/m 2 /mouse starting the day after viral delivery, whilst a lower tolerance in nude mice dictated a dose of 75 mg/m 2 /day. Fludarabine and 6MEPDR were also used for studies of PNP expression. Fludarabine was synthesized and purified by HPLC at CSIRO Molecular Science by Dr S Marcuccio. 6MEPDR was synthesized and purified by HPLC as previously described. 54 Both compounds were stored on dessicant in powder form at -20°C.
Transduction of cells in vitro
Cells were transduced in vitro at varying multiplicities of infection (MOI; defined as particles per cell) by removing the medium, allowing virus in PBS to adsorb for 30 min with gentle rocking and adding complete medium.
PNP assays
To compare the potency of batches of OAdV220 and to determine the level of PNP activity, PC3 or RM1 cells in 24-well plates were infected at MOIs of 10 2 -10 4 particles per cell. At 4 days after infection cells were scraped in 0.1 ml PBS and lysed by three freeze/thawing cycles. PNP activity was determined by assaying the ability of cell lysates (usually 5 l) to convert 6MEPDR to 6MEP. Lysate was incubated in a 1.2 ml reaction volume with 500 nmoles of 6MEPDR for 2 h or overnight at 37°C before stopping the reaction by heating to 100°C for 5 min. Conversion of pro-drug to metabolite was monitored by HPLC using a Millipore C18 column pre-equilibrated with 50 mM NH 4 H 2 PO 4 /5% acetonitrile for 30 min (flow rate 1 ml/min). Sample (50 l) was applied to the column and fractionated in the same ammonium phosphate/acetonitrile buffer (isocratic gradient) at a flow rate of 1.5 ml/min. The elution profile was detected by UV absorbance at 254 nm and the relative amounts of material in the substrate and product peaks were determined by calculating the area under the curve for each peak.
For assays of PNP activity in vivo, tumors were harvested, frozen and homogenized in 0.4-1.2 ml of 50 mM potassium phosphate buffer, pH 7.4, depending on tumor size and subjected to three rounds of snap freezing on dry ice, then thawing in a 37°C water bath to complete cell lysis. Cell debris was removed by centrifugation for 5 min at 15 000 g and supernatants transferred to fresh tubes on ice. Protein concentration was measured using a BCA test kit (Pierce, Rockford, IL, USA) and 500 g was taken for PNP assay as described above.
Effects of GDEPT in vivo
Three models of RM1 tumor growth in C57BL/6 were studied, whilst human PC3 cells were grown s.c. in BALB/c nude mice. C57BL/6 mice or nude mice were treated for 5 days i.p. with fludarabine phosphate at 600 mg/m 2 /day or 75 mg/m 2 /day, respectively, starting 1 day after intra-tumoral virus inoculation. Differences in dosages related to the relative tolerances of the mouse strains. Experiments were performed twice. . 55 Tumor volume and mouse survival were monitored three times/week. Similar experiments were performed using PC3 tumors generated in nude mice by s.c. injection of 1.5 × 10 6 cells/tumor. Once the tumors reached 5 × 5 mm (65 mm 3 ), mice were given a single intratumoral injection of OAdV220 on day 0, and then treated with fludarabine phosphate i.p. for the next 5 days. Treatment groups received fludarabine phosphate alone, OAdV220 alone and OAdV220 used with fludarabine phosphate.
Orthotopic tumors for in vivo transduction: On day 0, 5 × 10 3 RM1 tumor cells were injected into the prostatic capsule of C57BL/6 mice following a low abdominal transverse incision. On day 4, mice were anesthetized and the previous incision re-opened for direct intraprostatic injection of OAdV220 or control. Groups of mice received: OAdV220 (10 10 opu/tumor) ± fludarabine phosphate or control injections ± fludarabine phosphate on day 4. The mice were weighed twice weekly, and killed on day 18. Prostate volume was determined as for s.c. tumors and tissues were processed for histology. They were placed in formalin, paraffin-embedded, cut in 4-5-m sections and stained with hematoxylin and eosin.
Data presentation
For all animal experiments, data were presented as mean tumor volume ± s.e.m. versus time (days following virus injection). A computer-generated line of best fit was produced for each treatment curve. The overall ability to suppress tumor growth was determined from the time (t; days) taken to reach the midpoint of maximal RM1 tumor growth (2500 mm 3 ), extrapolated from the line of best fit. All treatments were compared with the appropriate control group. Suppression in tumor growth was calculated as follows: Percentage tumor reduction = (t treatmentt control )/t treatment × 100.
Statistics
Individual tumor volumes were entered for analysis using GraphPad PRIZM for PC. GDEPT treatment and control group tumor volumes were compared using the Mann-Whitney U test for non-parametric data at a single time point.
